Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 199

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 199
---
078 8 3,599 4,685 Pharmaceutical manufacturing, research and development— 2,203 — 2,203 Change in fair value of acquisition-related contingent consideration— (4,900)— (4,900)Depreciation and amortization expense— 1,316 83 1,399 General and administrative expense449 2,967 8,071 11,487 Other income (expense), net7,194 — (408)6,786 Income tax expense— — 4,884 4,884 Net income (loss)34,251 (3,718)(17,045)13,488 Year Ended December 31, 2023Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$36,346 $1,202 $— $37,548 Other revenue204 2 6 212 Provision for credit losses1,912 — — 1,912 Impairment of goodwill— 8,404 — 8,404 Interest expense982 3 864 1,849 Pharmaceutical manufacturing, research and development expense— 3,436 — 3,436 Depreciation and amortization expense— 2,525 52 2,577 Change in fair value of acquisition-related contingent consideration— (6,300)— (6,300)General and administrative expense527 2,875 7,830 11,232 Other expense, net(13)(24)— (37)Income tax benefit— — (1,274)(1,274)Net income (loss)33,116 (9,763)(7,466)15,887 Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate employees, which have been included for purposes of reconciling to the consolidated amounts. 

66

The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):December 31,20242023Total AssetsFinance Receivables$299,248 $288,735 Pharmaceutical Development and Other7,786 14,375 Holdings Company and Other25,201 31,144 Total$332,235 $334,254